Frequency, phenotype, outcome and therapeutic impact of skin reactions following initiation of adalimumab therapy: experience from a consecutive cohort of inflammatory bowel disease patients

Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic review

“…Studies in patients with inflammatory bowel disease who were treated with subcutaneous anti-tumour necrosis factor alpha inhibitors demonstrated a relatively high incidence of skin reactions and a broad spectrum of cutaneous adverse events. 127 Similar high incidences were reported for rheumatoid arthritis patients treated with daily subcutaneous injections of a interleukin-1 receptor antagonist. 128 The occurrence of skin reactions may lead to cessation of the DMT or switching to another type DMT.…”

PTH-113 Clinical Response to Induction Anti-Tnf Therapy has no Effect on Haemoglobin Levels in Patients with IBD

“…[c1] In our cohort few patients had to stop therapy which is similar to some (1) , but not all reported studies (2,3) . Less than half of affected patients received consultant dermatological review.…”

Cutaneous Adverse Reactions during Anti-Tnf Alpha Treatment for Inflammatory Bowel Diseases: The Experience of the Dermatology Clinic of Cagliari

“…A paradox effect of anti-TNF inducing psoriasis onset is significantly reported in the literature, with rates between 12%-18% [19][20][21]50] in patients treated with Adalimumab and 6.6% in those taking Infliximab [50]. Incidence of such events in our sample was quite lower, without differences among drugs, all patients affected with Crohn's disease.…”

“…In the most severe reaction, adalimumab was discontinuated and the decision to switch to Infliximab better controlled the disease, with complete remission after 2 months. The pathophysiologic mechanism underlying this paradoxical effect has not yet been clarified: a claimed hypothesis is that the cytokines imbalance might lead to excessive dendritic cells production of IFN, in genetically predisposed individuals [19]. It is also possible that genetic polymorphisms play a role in blocking TNFα: future genomic study of patients with such events could clarify the mechanisms triggering these reactions [51].…”

“…A wide range of skin manifestations has been described: infusion systemic reactions and at the injection site [16,17], infectious complications [18], eczematous dermatitis [13,19], psoriasis [20,21], and non-melanoma skin cancer [22,23].…”